GlassScriptPhysician profile
William C Mclain
NPI 1467426650
$3,021.29
in general payments reported to CMS, 2019-2025
16 companies · $661 in 2025
The $661 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $381 · 2021: $1,071 · 2022: $429 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $661.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $661.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $787.33 | 2019-2022 | |
| Eli Lilly and Company | $639.77 | 2025 | Trulicity |
| Harmony Biosciences LLC | $303.77 | 2020-2022 | |
| Eisai INC. | $249.79 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $213.88 | 2019-2022 | |
| Fisher & Paykel Healthcare INC | $192.47 | 2019-2022 | |
| Inspire Medical Systems, INC. | $134.97 | 2021 | |
| Merck Sharp & Dohme LLC | $114.76 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $96.50 | 2021 | |
| Resmed Corp | $87.96 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $84.00 | 2020-2021 | |
| Philips North America LLC | $46.88 | 2020-2021 | |
| Daiichi Sankyo INC. | $21.27 | 2025 | Datroway |
| Supernus Pharmaceuticals, INC. | $19.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.18 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.